David L. Porter, MD

Dr. Porter distinguishes community-based CAR T-cell therapy from non-accredited care, describing why extending treatment beyond academic centers demands the same rigorous standards patients already expect.

Dr. Porter argues FACT accreditation's original rationale for CAR T-cell therapy still holds, even as the standards evolve to fit community programs without loosening quality or safety requirements.

Dr. Porter frames access as CAR T-cell therapy's central challenge, outlining the safety, efficacy, and affordability gains still needed before outpatient administration can meaningfully close the gap for patients.